BI's Praxbind US Approval May Boost Pradaxa Sales

The FDA on Oct. 16 gave privately held Boehringer Ingelheim GmgH the go-ahead to market its humanized monoclonal antibody fragment Praxbind (idarucizumab) under an accelerated approval as an agent to reverse the blood-thinning effects of the company's highly popular anticoagulant Pradaxa (dabigatran) in emergency surgery or urgent procedures or in situations when there's life-threatening or uncontrolled bleeding.